Il rapporto
Notizie verificate su finanziamenti, sedi centrali e leadership delle aziende più innovative al mondo
105 report e oltre
GT Medical Technologies Raises $100M Series E for Brain Tumor Radiotherapy Implant
GT Medical Technologies raised a $100 million Series E led by new investor Viking Global Investors to accelerate commercial and operational initiatives for its GammaTile brain tumor therapy.
NeuroLink Brain Raises $580M Series D to Transform Healthcare
NeuroLink Brain secures $580M in Series D funding at $8.2B valuation to complete fda approval process, scale manufacturing for clinical deployment, and expand treatment applications.
Brainly Headquarters
Brainly headquarters location in Krakow, Lesser Poland. Peer learning platform
BrainNet Collective Secures $2.2B Series F for Cosmic-Scale Brain Networking Technology
BrainNet Collective achieves $2.2B in Series F funding at $32.1B valuation to pioneer revolutionary brain networking technology that could transform human civilization.
Precision Neuroscience Raises $102M Series C | Brain-Computer Interface
Brain-computer interface company Precision Neuroscience secures $102 million Series C led by B Capital.
ArsenalBio Raises $325M Series C
Cell therapy company advancing programmable CAR-T and TIL therapies for cancer treatment with focus on solid tumors
Galvenize Therapeutics Raises $100M Series C to Transform MedTech
Galvenize Therapeutics has secured $100M Series C in funding to accelerate growth and innovation in the medtech sector. Medical device company developing pulsed electric field therapies for cardiac ablation and tumor treatment...
Rakuten Medical Raises $100M Series F | Photoimmunotherapy Cancer Treatment
Cancer treatment company Rakuten Medical secures $100 million Series F led by TaiAx for Phase 3 trials.
Neuralink raises $600M Series at $9B valuation
Neuralink raises $600M in Series at $9B valuation. Brain-computer interface company developing brain implants...
Visualizzazione di 9 report • Pagina 1 • Categoria: all
Rimani avanti rispetto al mercato
Ricevi insight settimanali nella tua casella di posta. Niente spam, solo intelligenza.